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Previous studies have shown that decorin expression is signifi-
cantly reduced in colorectal cancer tissues and cancer cells, and
genetic deletion of the decorin gene is sufficient to cause intestinal
tumor formation in mice, resulting from a downregulation of p21,
p27kip1 and E-cadherin and an upregulation of b-catenin signal-
ing [Bi,X. et al. (2008) Genetic deficiency of decorin causes intes-
tinal tumor formation through disruption of intestinal cell
maturation. Carcinogenesis, 29, 1435–1440]. However, the regu-
lation of E-cadherin by decorin and its implication in cancer for-
mation and metastasis is largely unknown. Using a decorin
knockout mouse model (Dcn2/2 mice) and manipulated expres-
sion of decorin in human colorectal cancer cells, we found that
E-cadherin, a protein that regulates cell–cell adhesion, epithelial–
mesenchymal transition and metastasis, was almost completely
lost inDcn2/2mouse intestine, and loss of decorin and E-cadherin
accelerated colon cancer cell growth and invasion in Dcn2/2mice.
However, increasing decorin expression in colorectal cancer cells
attenuated cancer cell malignancy, including inhibition of cancer
cell proliferation, promotion of apoptosis and importantly, atten-
uation of cancer cell migration. All these changes were linked to
the regulation of E-cadherin by decorin. Moreover, overexpres-
sion of decorin upregulated E-cadherin through increasing of
E-cadherin protein stability as E-cadherin messenger RNA and
promoter activity were not affected. Co-immunoprecipitation as-
say showed a physical binding between decorin and E-cadherin
proteins. Taken together, our results provide direct evidence that
decorin-mediated inhibition of colorectal cancer growth and
migration are through the interaction with and stabilization of
E-cadherin.
Introduction
Decorin is a member of the small leucine-rich proteoglycan family
that is primarily synthesized by fibroblasts and myofibroblasts and
regulates collagen fibrillogenesis. It is also involved in a number of
physiological and pathological processes including the control of
osteogenic stem cells, muscular development, wound healing and
cancer (1,2). Several studies have shown tumor suppressor function
of decorin. Decorin expression levels are significantly reduced in
human colorectal cancer tissues (3). Increasing decorin expression
in colon, breast and squamous cancer cell lines suppresses their
growth and progression. These effects are associated with the induc-
tion of p21 (4–6), interaction with transforming growth factor b
(5,7,8) and epithelial growth factor receptor (EGFR) (9–11). Loss
of decorin accelerates malignant lymphomas in p53 mutant mice,
leading to early mortality (12). Low levels of decorin in invasive
breast carcinomas are associated with larger tumor size, shortened
time to progression and poor outcome (13). Similarly, low decorin
levels are also correlated with accelerated lung cancer progression
(14). In contrast, administration with human recombinant decorin or
infection with a decorin-expressing adenovirus inhibited breast cancer
cell growth and prevented pulmonary metastasis in nude mice through
decorin’s long-term downregulation of the ErbB2 tyrosine kinase cas-
cade (15,16).
Earlier study showed that the mice in a mixture background with
a targeted disruption of the decorin gene do not develop spontaneous
tumors (17). Our recent work showed decorin deficiency could cause
spontaneous intestinal tumor formation in the mice that are in C57Bl/6
background (3). The mechanism of tumorigenesis involves downregu-
lation of p21, p27 and E-cadherin and upregulation of the b-catenin
signaling. Further study showed that decorin could interact with
Met, which induces transient receptor activation, recruits E3
ubiquintin ligase c-Cbl and rapid intracellular degradation of Met
and finally leads to a suppression of b-catenin, a downstream Met
effector (18).
Numerous studies have demonstrated that loss of E-cadherin enhan-
ces cancer metastasis through modulation of epithelial–mesenchymal
transition, and increase of E-cadherin expression could prevent tumor
invasion and metastasis (19,20). However, how decorin affects
E-cadherin and whether the effect of E-cadherin by decorin plays a role
in tumor formation and metastasis are still unknown. Herein, we
showed that decorin could stabilize E-cadherin protein and physically
interacted with E-cadherin, leading to attenuation of colorectal cancer
growth and migration in vitro and in decorin knockout mice.
Materials and methods
Mouse intestine collection and immunohistochemical staining
Mouse intestinal tissues from Dcn/ and Dcnþ/þ mice (C57Bl/6 background)
were collected, fixed in 10% buffered formalin and embedded in paraffin, as
reported by us (3). Four micrometer of sections were utilized for immunohis-
tochemical staining using anti-E-cadherin antibody (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA). The procedure was similar as reported (3). In brief, the
sections were deparaffined, rehydrated, quenched with 3% H2O2 and blocked
with 10% normal serum, then incubated with E-cadherin antibody overnight at
4C, followed by incubation with secondary antibody and avidin–biotin
complex (ABC kit, Vector Laboratory, Burlingame, CA). The staining was
developed by using 3#, 5#-diaminobenzidine and finalized with lightly counter
staining with hematoxylin. The stained slide image was captured by Aperio
Image System (Vista, CA).
Cell lines
Human colon cancer cell line HCT116 was cultured in McCoy’s 5A Medium
(Invitrogen, Carlsbad, CA). The murine colon adenocarcinoma cell line MC38
(derived from C57BL6/J mouse) (21) was cultured in Modified Eagle’s medium
(Invitrogen). Human embryonic kidney HEK293 cells were cultured in
Dulbecco’s modified Eagle’s medium (Invitrogen). All media were supple-
mented with 10% fetal bovine serum and antibiotics (10 000 U/ml penicillin,
10 lg/ml streptomycin). Cells were cultured at 37C in a humidified atmosphere
containing 5% CO2.
Xenografts
Murine colon adenocarcinoma cells MC38 (2.5  106) were injected subcu-
taneously into the flank of the Dcn/ or Dcnþ/þ mice at age about 8 weeks
(five mice per group). Both MC38 cell line and Dcn mice were in C57BL/6
background. The animals were maintained in a pathogen-free barrier facility at
the University of Illinois at Chicago Biological Resources Laboratory and
closely monitored by animal facility staff. Fourteen days after injection, the
animals were killed and the xenografts were isolated, the weight (g) and
volume (mm3) of the xenografts were determined. All procedures were
conducted according to the Animal Care and Use guideline approved by the
University of Illinois at Chicago Animal Care Committee.
Abbreviations: EGFR, epithelial growth factor receptor; mRNA, messenger
RNA; siRNA, small interfering RNA.
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Decorin overexpressing plasmid construction and transfection
A human decorin expression plasmid (pcDNA3-DCN) was generated using
normal colon mucosa complementary DNA as template for polymerase chain
reaction amplification and subcloning into the pcDNA3-HA vector (Clontech
Laboratories, Mountain View, CA) using the following primers: forward 5#-
CCGCTCGAGATGAA GGCCACTATCATCCTC-3# and reverse 5#-GAA-
GATCTTTACTTATAGTT TCCGAGTT-3#. The polymerase chain reaction
product was digested with XhoI and Bgl II and the digested products were
ligated into the vector. Transient transfection of HCT116 cells with pcDNA3-
DCN or pcDNA3-HA vector control was performed via Lipofectamine 2000
(Invitrogen). Cells were subject to different assays, 24–72 h after transfection.
Small interfering RNA and transfection
A small interfering RNA (siRNA) targeting human decorin (si-DCN) and
a scramble control siRNA were purchased from the Integrated DNA Technolo-
gies (Skokie, IL). The siRNAs were transfected into the HEK293 cells using
Lipofectamine 2000 (Invitrogen). The cells were collected after 48 h transfection
and were subjected for immunoblotting to determine the changes of E-cadherin.
Immunoblotting
For immunoblotting, cells were collected 72 h after transfection. Cells were lysed
using 1X RIPA buffer (Upstate Biotechnology, Lake Placid, NY) containing
a protease inhibitor cocktail (Sigma, St Louis, MO). After cell lysis, 30 lg of
protein was loaded on a 10% sodium dodecyl sulfate gel followed by transfer to
polyvinylidene difluoride membrane. Antibodies against decorin (a gift from Dr
Fisher, NIH), E-cadherin, p21, b-catenin (Santa Cruz) and b-actin (Tianjin Sun-
gene Biotech, Tianjin, China) were used. Secondary antibody was purchased
from Santa Cruz Biotechnology. The detected signals of immunoblotting were
visualized by an enhanced chemiluminescence reaction system (ECL Plus,
Amersham, Piscataway, NJ), as recommended by the manufacturer.
Proliferation, apoptosis and migration analysis
Cell proliferation was analyzed by MTS assay according to the manufacture’s
protocol (Promega, Madison, WI). To detect apoptosis, cells treated with recombi-
nant decorin core protein (Sigma) or phosphate-buffered saline, respectively, were
harvested and fixed with 70% ethanol followed by propidium iodide buffer stain-
ing. Cells were then counted by flow cytometry (FACScan, BD Biosciences, San
Jose, CA). Cell migration was detected using a transwell plate (Corning, Lowell,
MA) followed by 4#,6-diamidino-2-phenylindole staining after 48 h of transient
transfection with pcDNA3-DCN or pcDNA3-HA vector, respectively.
Wound healing assay
HCT116 cells transiently transfected with pcDNA3-DCN or pcDNA3-HA
vector were seeded in a 100 mm Petri dish. A wound was made by scratching
on the Petri dish bottom, followed by another 24 h growth. The distance of the
wound was measured under microscope.
Messenger RNA levels analysis
Total RNA was extracted from the HCT116 cells and messenger RNA (mRNA)
levels of E-cadherin and decorin were analyzed using real-time quantitative
reverse transcription–polymerase chain reaction as described recently (22).
The primers for E-cadherin were: forward 5#-tgcccagaaaatgaaaaagg-3# and
reverse 5#-gtgtatgtggcaatgcgttc-3#. The primers for decorin were: forward
5#-cgagtggtccagtgttctga-3# and reverse 5#-aaagccccattttcaattcc-3#. Actin was
used as internal control (3).
E-cadherin promoter activity analysis
HCT116 cells were co-transfected with a pGL4 empty vector or pGL4-E-
cadherin-Luc plasmid, which contains the full-length E-cadherin promoter
(a gift from Dr M.Saitoh) (23), with pcDNA3-DCN or pcDNA3-HA vector.
Renilla was co-transfected as an internal control. Forty-eight hours after trans-
fection, dual luciferase activity kit (Promega, Madison, WI) was used in com-
bination with a luminometer to measure luciferase activity of the cells according
to the manufacturers’ protocol.
E-cadherin protein stability analysis
HCT116 cells were transiently transfected with pcDNA3-DCN or pcDNA3-
HA vector, followed by exposure to protein synthesis inhibitor cycloheximide
(50 lg/ml; Sigma). The cells were harvested after 4, 6 and 8 h. E-cadherin
protein levels were analyzed by immunoblotting.
Co-immunoprecipitation analysis
Similar as described recently (24), HCT116 cells with transfection of decorin
expression plasmid pcDNA3-DCN or empty vector pcDNA3-HA were harvested
after 24 h transfection, the cells were lysed in RIPA lysis buffer (20 mM Tris–
HCL, pH 8.0, 150 mM NaCl, 1% Triton X-100, protease inhibitor cocktail), and
then the cell lysates were immunoprecipitated with anti-E-cadherin antibody, and
the immunocomplex was then probed with anti-HA antibody (for decorin). Vice
versa, the cell lysates were immunoprecipitated with anti-HA antibody (recog-
nition of decorin), the immunocomplex was then probed with anti-E-cadherin
antibody. The immunocomplex was visualized using enhanced chemilumines-
cence reagent (Amersham Biosciences, Piscataway, NJ). The signal was quanti-
fied using Quantity One software (Bio-Rad, Hercules, CA)
Results
E-Cadherin was dramatically reduced in Dcn/ mouse intestine
Early characterization of Dcn/ mice has shown intestinal tumor for-
mation and potential changes at molecular levels (3), in which cyclin-
dependent inhibitors p21 and p27 were decreased, and Wnt/b-catenin
signaling was increased, and in contrast, E-cadherin, a critical partner
of b-catenin, was decreased. To determine the effect of E-cadherin by
decorin in situ, we performed immunohistochemical staining. As
shown in Figure 1A, E-cadherin was dramatically reduced or almost
absent in the small intestine of the Dcn/ mice compared with that in
the Dcnþ/þ mice.
Knockdown decorin expression led to reduced expression of
E-cadherin in vitro
To validate decorin-caused reduction of E-cadherin in vitro, we trans-
fected the HEK293 cells with a siRNA targeting decorin (si-DCN) to
knockdown decorin expression and found that E-cadherin was also
reduced compared with the control (Figure 1B).
Loss of decorin accelerated cancer cell growth and invasion in mice
To determine whether decorin-mediated loss of E-cadherin influences
tumor growth and invasion in mice, we inoculated murine colon car-
cinoma MC38 cells (C57BL/6 background) (2.5  106 cells per mice)
subcutaneously in Dcn/ and þ/þ mice (C57BL/6 background) for
14 days. Compared with the wild-type mice that had single and smaller
Fig. 1. Loss of decorin reduced E-cadherin expression in mouse and in vitro.
(A) E-cadherin was dramatically reduced in intestinal epithelial cells in
Dcn/ mice by immnunohistochemical staining (anti-E-cadherin antibody
dilution 1:100) (magnification 10 and 40, respectively). (B) Knockdown
decorin expression via decorin siRNA (si-DCN) led to reduced expression of
E-cadherin in HEK293 cells compared with the control. The first two lanes
stood for that the cell lysated was obtained from duplicated experiments. So
did the last two lanes of control. The average levels of E-cadherin were
quantified and showed in the right panel. P , 0.05 compared with the
control group.
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tumor as usually seen in nude mice, one Dcn/ mouse had two tumors
(xenografts) and another one had three tumors (Figure 2A, P. 0.05). In
addition, the sizes (weight in grams) of the tumors in the decorin knock-
out mice were larger than those in decorin wild-type mice (1.62 ± 0.41 g
per mouse in Dcn/ mice versus 0.58 ± 0.12 g per mouse in Dcnþ/þ
mice) (Figure 2B,P5 0.04). Impressively, tumor invasions to the muscle
and abdominal were also observed in Dcn/ mice (image not shown).
Overexpression of decorin inhibited cancer cell growth and migration
and slowered wound healing in vitro
To elucidate whether restore decorin expression attenuates cancer cell
malignancy, we treated human colon cancer cells HCT116 with 1 lg/ml
or 3 lg/ml of recombinant decorin protein (Sigma) for 24 h. We found
that decorin protein indeed inhibited cell proliferation by 22%
(Figure 3A, P , 0.05) and promoted apoptosis by 14-fold (Figure 3B,
P , 0.01). Decorin overexpression plasmid pcDNA3-DCN was then
transfected into the HCT116 cell. We found that increasing expression
was able to inhibit cancer cell migration using transwell (Figure 3C and
E) and wound healing approaches (Figure 3D and F).
Increasing decorin expression upregulated E-cadherin protein level
and did not affect E-cadherin mRNA and promoter activity
To determine whether decorin involved inhibition of malignancy was
associated with E-cadherin, we first determined the changes of
E-cadherin at protein level and found that overexpression of decorin
upregulated the expression of E-cadherin and p21WAF1 in HCT116
cells. However, overexpression of decorin suppressed b-catenin and
CDK4 proteins (Figure 4A).
We then determined whether decorin affected E-cadherin at tran-
scriptional levels by analyzing E-cadherin mRNA and promoter
activity. Unexpected, E-cadherin mRNA level, unlike E-cadherin pro-
tein level, was only slightly increased by increasing overexpression of
decorin (Figure 4B, P . 0.05), and E-cadherin promoter activity was
not significantly increased either (Figure 4C, P . 0.05), assayed by
quantitative reverse transcription–polymerase chain reaction and
measuring promoter luciferase activities, respectively.
Decorin stabilized E-cadherin protein
To elucidate the underlying mechanism of that decorin upregulated
E-cadherin at protein level but did not alter E-cadherin at transcriptional
levels, we conducted protein stability experiments. We transfected the
HCT116 cells with decorin-expressing plasmid pcDNA3-DCN or
empty vector pcDNA3-HA and treated the cells with protein synthesis
inhibitor cycloheximide (50 lg/ml). As shown in Figure 5, increasing
decorin expression indeed prolonged the half life of E-cadherin protein,
indicating that decorin could stabilize E-cadherin protein.
Decorin physically bound to E-cadherin
To determine whether there is an interaction between decorin and
E-cadherin proteins, we performed co-immunoprecipitation assay.
Since decorin is almost undetectable in the HCT116 cells, we trans-
fected the HCT116 cells with decorin-expressing plasmid, precipitated
the cell lysates with anti-E-cadherin and probed with anti-HA antibody
to recognize decorin. We found an immunocomplex of E-cadherin and
decorin (Figure 6A). Vice versa, an immunocomplex was also seen
using anti-HA antibody to pull down and anti-E-cadherin antibody to
probe. Both approaches demonstrated the physical binding between
decorin and E-cadherin proteins.
Discussion
Colorectal cancer is the third most common cancer and is the second
leading cause of cancer-related deaths in the USA (25), mainly due to
invasion and metastasis. However, the underlying mechanisms of me-
tastasis are largely unknown. Herein, we report that loss of decorin
accelerated colorectal cancer cell growth and invasion in mice and
increase of decorin inhibited cancer cell proliferation and migration,
and promoted apoptosis, which was directly linked to E-cadherin—
stabilization by decorin and physical binding with decorin.
E-cadherin is a single-span transmembrane glycoprotein that
mediates cell–cell adhesion through calcium-dependent homophilic
interactions of extracellular domains (26). Perturbation of E-cadherin-
mediated cell adhesion is involved in tumor progression, metastasis
and poor prognosis (27–32), and loss of E-cadherin expression or
function in vitro has been associated with decreased differentiation
and increased invasive capacity of cancer cell lines (26). Growing
evidence suggests the importance of E-cadherin in carcinogenesis
and cancer metastasis and the potential regulation of E-cadherin by
Fig. 2. Loss of decorin led to enhancement of colon cancer cell growth in
mouse xenografts. Murine colon cancer cells MC38 (2.5106) (250 ll) were
subcutaneously injected into the flank of Dcnþ/þ or / mice (five mice per
group). Fourteen days post inoculation, the xenografts were excised and
weighed. Each spot represents one mouse.
Fig. 3. Decorin core protein treatment suppressed cell proliferation
(A) promoted apoptosis (B) in HCT116 cells. P , 0.05 and P , 0.01
compared with the control group. Increasing decorin expression in colon cancer
cells HCT116 inhibited cell migration (C) and wound healing (D). The migrated
cell numbers (mean ± SD) were quantified in (E), and the wound distances
(mean ± SD) were measured and presented in (F) (‘—’ equals to 1000 lm). All
experiments were triplicated independently. pcDNA3-DCN indicated the cells
with transfection of decorin overexpression plasmid, pcDNA3-HA indicated the
cells with transfection of pcDNA3-HA vector control.
X.Bi et al.
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GSK3b, snail/slug and Akt/PKB (33–35). E-cadherin loss promotes
metastasis by disaggregating cancer cells from another, activates spe-
cific downstream signal transduction pathways and causes epithelial–
mesenchymal transition, which facilitates metastasis. However,
maintenance of E-cadherin expression could restore epithelial
morphology and prevent tumor invasion and metastasis (19,20).
In colorectal cancer, both Apc mutations and E-cadherin downre-
gulation are linked to increased b-catenin expression (36). The APC
gene is mutated in up to 80% of sporadic human colon cancers and
loss of APC has been shown to induce irregular stabilization and accu-
mulation of b-catenin because of a decrease in the binding among the
APC/GSK3b/Axin complex, the complex in the cytoplasm that controls
b-catenin stability via phosphorylation and proteasomal degradation
(36). b-catenin is a key mediator in the Wnt signaling pathway and
plays an important role in intestinal cancer development (37). b-catenin
level and localization throughout the cell are controlled by E-cadherin.
Our characterization on the decorin knockout mice has demon-
strated the critical role of decorin in regulating of intestinal cell ho-
meostasis and tumor suppressor function, also demonstrated that
b-catenin signaling is activated through a non-canonic Wnt/b-catenin
pathway (3). Present study again revealed that dramatic loss of
E-cadherin by loss of decorin in vivo resulted in the acceleration of
tumor growth and invasion in Dcn/ mice, but upregulation
of E-cadherin by increase of decorin expression in vitro led to the atten-
uation of colorectal cancer cell malignancy. Both in vivo and in vitro
results strongly suggested the tumor suppression and anti-metastasis of
decorin in stromal and epithelial cells, respectively, which was through
regulatory interaction and stabilization of E-cadherin.
Although upregulation of E-cadherin protein by decorin was seen,
alterations of E-cadherin at transcriptional levels by decorin were not
significant. Besides protein stabilization, whether there are additional
mechanisms involved in the regulation of E-cadherin by decorin
and how these two proteins interacted are not completely clear.
Since HCT116 cell line is one of the most difficulty cell lines for trans-
fection, the transfection efficiency might affect the results, and thus,
should take consideration. An improvement of transfection efficiency
is needed for further investigation. Earlier studies found E-cadherin
could be ubiquitinated by a c-Cbl-like E3 ubiquitin ligase Hakai and
Fig. 4. Increasing expression of decorin in HCT116 cells upregulated the protein levels of p21 and E-cadherin and downregulated b-catenin and cdk4 (A) but only
slightly affected E-cadherin mRNA levels (B) and E-cadherin promoter activity (C). pcDNA3-DCN indicated the cells with transfection of decorin overexpression
plasmid, pcDNA3-HA indicated the cells with transfection of pcDNA3-HA vector control. b-actin was used as internal loading control.
Fig. 5. Increasing decorin expression enhanced endogenous E-cadherin
protein stability in HCT116 cells. HCT116 cells were transfected with
decorin expression plasmid (pcDNA3-DCN) or corresponding empty vector
(pcDNA-HA), followed by exposure to the protein synthesis inhibitor
cycloheximide (50 lg/ml) for different times. Protein levels were analyzed
by immunoblotting (A) and the changes of proteins were quantified (B).
b-actin was used as internal loading control.
Fig. 6. There was a physical binding between decorin and E-cadherin
proteins. The HCT116 cells were transfected with decorin-expressing plasmid
(pcDAN3-DCN) or vector (pcDNA3-HA) for 48 h and the cells were harvested
for lysate. The cell lysates were precipitated by anti-E-cadherin antibody and
probed with anti-HA antibody to recognize decorin (A). Vice versa, the cell
lysates were precipitated by anti-HA antibody and probed with anti-E-cadherin
antibody to recognize E-cadherin (B). IgG was used as negative control.
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then is induced to the internalization of E-cadherin (38,39). The latest
study showed proteasome-dependent events are likely to be involved in
stabilization of cell surface E-cadherin (40). As mentioned above, decor-
in in tumor suppression is also associated with EGFR and cell cycle
inhibitors p21 and p27. Importantly, the regulation between E-cadherin
and EGFR, p21 and p27, also has been reported (41–44). Our data
showed a direct interaction between decorin and E-cadherin, but whether
the proteasome pathway is also involved in the direct regulation of those
two proteins or whether the regulation is mediated by other factors like
EGFR, p21 or p27 are unknown and need further investigation.
In summary, this study identified additional antitumor and anti-
metastasis functions of decorin, which was linked to the E-cadherin
stabilization and regulatory interaction. This study also demonstrated
translational potential of decorin as a therapeutic and preventive agent
for malignant diseases.
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